PROLUNG IS NOW IONIQ SCIENCES

A Modern Approach to Early Cancer Detection

Detecting the Body's Earliest Response to Cancer

EIA + AI = IONIQ Sciences

The body’s electrical properties change in the presence of cancer.

The IONIQ System utilizes Electrical Impedance Analytics (EIA) to take up to 13,125 electrical readings of the body over a 20 minute period. 

Our proprietary algorithm processes this data to determine the likelihood of malignancy in its earliest, most-treatable stages.

IONIQ is integrating Artificial Intelligence (AI) to further improve performance and expand from its “Breakthrough” ProLung Test to a Multi-Cancer Screen.

IONIQ’s patented technology allows us to non-invasively detect the presence of malignancy in its earliest stages, potentially improving survival and reducing costs.

 

Screen Shot 2020-05-24 at 4.36.10 PM

Clinical Evidence

0
STUDIES & TRIALS
0
CLINCIAL SITES
0
SUBJECTS
0 M+
DATA POINTS

Modern Cancer Screen

Over the last 15 years we have worked with premier institutions around the world accumulating a substantial library of clinical evidence resulting in a Breakthrough Device Designation from the US FDA for our ProLung Test. From this foundation, we are transitioning from developing a single Lung Cancer Test to developing a Multi-Cancer Screen.